Larimar Therapeutics, Inc. (LRMR) Stock Ticker
LRMR right now
Market factors today
Unlock the full LRMR picture
About Larimar Therapeutics, Inc.
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
LRMR stock facts
| Ticker symbol | LRMR |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $319.4M |
| CEO | Carole S. Ben-Maimon |
| Employees | 71 |
| Headquarters | Bala Cynwyd, PA, US |
| IPO date | 2014-06-19 |
| Website | www.larimartx.com |
What you can see for LRMR on Tickr
Live LRMR price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the LRMR report.
Rankings
FAQ
What is the ticker symbol for Larimar Therapeutics, Inc.?
The ticker symbol for Larimar Therapeutics, Inc. is LRMR, listed on the NASDAQ Global Market.
What is LRMR?
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed…